Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRSN
DateTimeSourceHeadlineSymbolCompany
06/01/202514:00PR Newswire (US)NeuroSense Regains Compliance with Nasdaq's Minimum Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
23/12/202414:00PR Newswire (US)NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALSNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/12/202415:25PR Newswire (US)NeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
11/12/202414:25PR Newswire (US)NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeCNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202413:30PR Newswire (US)NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALSNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/12/202413:30PR Newswire (US)NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/11/202414:20PR Newswire (US)NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MNDNASDAQ:NRSNNeuroSense Therapeutics Ltd
28/10/202412:30PR Newswire (US)NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/10/202412:30PR Newswire (US)New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
15/10/202413:15PR Newswire (US)NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further UpdatesNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/10/202413:00PR Newswire (US)NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in CanadaNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/10/202413:00PR Newswire (US)NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/09/202413:05PR Newswire (US)NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer'sNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/09/202413:00PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
30/08/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
30/08/202420:30PR Newswire (US)NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:NRSNNeuroSense Therapeutics Ltd
28/08/202411:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
26/08/202412:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
16/08/202420:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
16/08/202420:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/08/202418:00PR Newswire (US)NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/08/202413:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/08/202413:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/08/202413:15PR Newswire (US)NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/07/202413:27PR Newswire (US)NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionNASDAQ:NRSNNeuroSense Therapeutics Ltd
01/07/202412:00PR Newswire (US)NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/06/202413:00PR Newswire (US)NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/06/202420:30PR Newswire (US)NeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealNASDAQ:NRSNNeuroSense Therapeutics Ltd
20/05/202413:00PR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/05/202413:05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN